PubMed:33754144 / 1713-1915
Annnotations
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T17 | 0-202 | Sentence | denotes | At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76). |
| T17 | 0-202 | Sentence | denotes | At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76). |
yangbin123xm_800_3
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 36-48 | CI | denotes | mavrilimumab |
| T13 | 143-150 | CI | denotes | placebo |
chenxin_473849_800_3
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T14 | 143-150 | CI | denotes | placebo |
| T9 | 36-48 | CI | denotes | mavrilimumab |